TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Phase Endometrial Scratch in IUI Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing intrauterine insemination procedures between the ages of 18 and 37 who have undergone a complete fertility work up (tubal, uterine, hormonal and sperm assessments) and do not have a current tubal or uterine factor infertility or severe male factor (expected to have \< 10 million total motile sperm on IUI sample) unless using donor sperm.~Exclusion Criteria:~* age \< 18 or \> 37, expectation (prior to randomization) of \< 10 million total motile sperm on IUI sample, tubal factor, uterine factor, incomplete fertility work up.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- Endometrial scratch (Type: EXPERIMENTAL): A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
- Sham procedure (Type: SHAM_COMPARATOR): A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in the lead-in study RVT-101-2001.~Exclusion Criteria:~* Any clinically relevant concomitant disease, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- RVT-101 35 mg (Type: EXPERIMENTAL): RVT-101 35 mg once daily
- RVT-101 70 mg (Type: EXPERIMENTAL): RVT-101 70 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \>=17 years with diagnosis of CD for at least 3 months defined by histology or radiology~* ileocolonic non-penetrating disease~* Moderate active CD with CDAI 250-450~* CRP level over normal range~* Stable CD therapy with a total steroid dose not exceeding 10mg prednisolone or equivalent for 4 weeks~Exclusion Criteria:~* Infection with enteric pathogen~* Usage of probiotics, antibiotics, or prebiotics within the last month~* Change in dose of oral steroids or 5-ASA within the last 4 weeks or AZA or MTX in the last 3 months~* Dose of steroids exceeds 10 mg prednisolone per day or equivalent~* Infusion of IFX or any alternative biological therapy within the last 3 months~* Use of rectal 5-ASA or steroids within the last 2 weeks.~* Imminent need for surgery or presence of severe disease (CDAI \>450)~* Pregnancy or lactation~* Short bowel syndrome or subtotal/total colectomy~* Pure anal disease and previous proctocolectomy~* Significant hepatic, renal, endocrine, respiratory, neurological or cardiovascular disease as determined by the principal investigator~* History of cancer with a disease-free state of less than two years~* Patients with penetrating disease or small bowel lesion only.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- pectin (Type: EXPERIMENTAL): Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
- control (Type: PLACEBO_COMPARATOR): Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of Rhythm Detection by a Wearable Smart Watch for Cardiac Arrhythmias (The WATCH-RHYTHM Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years old~* Patients who have an implantable loop recorder for heart rhythm monitoring purposes~* Having IOS iphone device that can be integrated into Apple Watch~* Willing to sign a consent form and participate in the study~Exclusion Criteria:~* Hemodynamically unstable patients~* Over 90 years of age~* Presence of wrist tattoos~* Presence of AV fistula on the wrist on which the wearable is worn. (If the contralateral wrist is unaffected, those patients can be included)~* Presence of Implantable Cardiac Pacemaker and/or ICD~* Patients with Parkinsons disease or tremors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Smart Watch (Type: OTHER): The patients will wear the Smart Watch to generate data to assess their rhythm as confirmed by the ILR done during the same time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RESIPI for Reducing Perioperative Major Adverse Cardiac Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Revised Cardiac Risk Index greater than or equal to 1, history of diastolic dysfunction, or age greater than 55 years.~* Surgery type: Major Abdominal Oncologic Surgery~* Planned surgery length greater than or equal to 90 minutes with planned in-patient stay of at least 2 days~Exclusion Criteria:~* Patients who are unstable by current American Heart Association/American College of Cardiology Clinical Practice Guidelines~* Patients with Chronic Kidney Disease Stage IV or V~* Urgent/emergent surgical interventions (e.g. Level 1 or 2 by VUMC VOR definitions)~* No signs of ischemia, congestive heart failure, or volume overload: Creatinine Clearance greater than 30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard intraoperative care- no interventions (Type: ACTIVE_COMPARATOR): Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
- RESIPI (Type: EXPERIMENTAL): Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of PICO Versus Standard Care in Chronic and Sub-acute Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years old~* Males and females. If female, they must not be pregnant or lactating. If female and of reproductive age, a pregnancy test will be provided.~* The patient or their legal representative (if the patient is incapable of giving legal consent), is able to understand the trial and is willing to consent to the trial.~* Patients with sub-acute or chronic wounds (diabetic foot ulcer, pressure ulcer, venous leg ulcer, or other chronic) suitable for treatment with a PICO dressing.~* Wound duration ≤52 weeks - Amended to remove criteria.~* Wound area range ≥5 cm2 at start of screening period~* Wound maximum linear dimension ≤ 15cm~* Able to use English for the interview~Exclusion Criteria:~* Patients with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing).~* Wounds which have an infection which is not being treated with systemic antibiotics.~* Wounds which are actively bleeding.~* Exposure of blood vessels, organs, bone or tendon at the base of the reference wound~* Exclude undermining or tunnelling present or suspected in the wound~* Use of negative pressure device on wound in the last 30 days. Amended to remove criteria~* Malignant wounds/malignancy in the wound~* Systemic infection not being treated with systemic antibiotics~* Simultaneous treatment with other experimental wound care procedures, biologics or devices~* Patients with a known history of poor compliance with medical treatment.~* Patients who have participated in this trial previously and who closed or were withdrawn.~* Patients who are unable to understand the aims and objectives of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PICO (Type: ACTIVE_COMPARATOR): PICO Negative Pressure Wound Therapy (NPWT) system
- Standard care (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Ultrasound Help Junior Anesthesia Residents With Placement of Labor Analgesia in Pregnant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous~* Term (\>37 weeks gestation)~* Vertex presentation~* Singleton gestation~* Ability to provide informed consent~* Request for analgesia for labor pain~* Maternal age 18 years or greater~Exclusion Criteria:~* Multiparous~* Preterm (\< 37 weeks gestation)~* Presentation other than vertex (breech, transverse)~* Active drug/alcohol dependence~* Previous spinal surgeries~* Known spinal deformities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound (Type: ACTIVE_COMPARATOR): Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
- No ultrasound (Type: ACTIVE_COMPARATOR): Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraductal Papillary Mucinous Neoplasm With Malignant Change

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who is suspected to have IPMN by imaging study or clinician~* Time interval between imaging study and surgery less than 2 months~Exclusion Criteria:~* Patients who have pathology results not by surgery~* Who is less than 20 years old~* Who cannot voluntarily agree study design

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Antibiotic Irrigation (Gentamicin) in Prophylaxis of Midfacial Fracture Surgical Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are planned for open reduction internal fixation of midfacial fractures as part of standard of care~* patients who are admitted to Memorial Hermann hospital at Texas Medical Center~* able to sign their own consent~Exclusion Criteria:~* infected surgical sites~* allergies to bacitracin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- topical irrigation with the antibiotic plus intravenous (IV) prophylactic antibiotic (Type: EXPERIMENTAL): Fractures will be topically irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.~\[previously, this arm involve topical irrigation with bacitracin topical antibiotic (50,000 units), but in April of 2020 the study was modified to use gentamycin rather than bacitracin, after the FDA warning of the toxic side effects of bacitracin and because the hospital where the study was conducted removed bacitracin from its formulary.\]
- topical irrigation with sterile normal saline (NS) plus intravenous (IV) prophylactic antibiotic (Type: ACTIVE_COMPARATOR): Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Videogame-based Incentives for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* smoking 10+ cigarettes per day~* smoking for 2+ years~* currently wishes to quit smoking~* has a computer at home with Internet access~* U.S. citizen~* literate~Exclusion Criteria:~* smoking other substances (e.g., marijuana, cigars) \> 2 times per month~* unstable medical or psychiatric condition that might interfere with the program~* living with someone who smokes in the home~* a job that exposes the person to excessive ambient carbon monoxide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Contingent (Type: EXPERIMENTAL): Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention
- Non-contingent (Type: ACTIVE_COMPARATOR): Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Extrapleural Intercostal Catheter vs. Thoracic Epidural for Thoracotomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral thoracotomy~* Video Assisted thoracotomy with high likely hood of converting to open thoracotmoy~Exclusion Criteria:~* Bilateral thoracotomy~* Planned bilateral thoracotomy~* Planned chest wall resection~* Planned combined thoracotomy and laparotomy procedure~* VATS procedure without conversion to unilateral thoracotomy~* Emergency operation~* Critically ill patients~* Patients who require an assistive device (i.e. cane, walker, or wheel chair) for mobility~* Patients who are unable to give informed consent~* Patients with preoperative chronic back or chest wall pain~* Empyema or other infective condition increasing the risk of epidural infection~* Coagulopathy~* Decision of the surgeon or anesthesiologist, or choice of the patient~* Infection at site of epidural placement~* Patients with other co morbidities which exclude thoracic epidural placement~* Patients under the age of 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous extra-pleural intercostal local anesthesia (Type: EXPERIMENTAL): intra-operatively placed extrapleural intercostal catheter
- Thoracic Epidural (Type: ACTIVE_COMPARATOR): gold standard

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with imatinib 400 mg~* Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis~* Able to tolerate chronic administration of imatinib at the highest dose (400-600 mg) the subject has received in the past~* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2~* Adequate hepatic and renal function~Exclusion Criteria:~* Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant~* Previous diagnosis of accelerated/blast crisis CML~* Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases~* Previous documentation of T315I mutation~* Uncontrolled or significant cardiovascular disease~* Serious uncontrolled medical disorder/active infection~* History of significant bleeding disorder unrelated to CML~* Intolerance to imatinib ≥400 mg~* Concurrent malignancies other than CML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 50-180 mg once daily (QD)
- B (Type: ACTIVE_COMPARATOR): 200-800 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of infection by SARS-CoV-2:~  1. symptoms of acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS-CoV-2 infection; OR~ 2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection; OR~ 3. severe acute respiratory infection (fever and at least one sign / symptom of respiratory disease eg cough, fever, shortness of breath) AND in need of hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection;~* Eastern Cooperative Oncology Group Performance Status score 0 to 1;~* National Early Warning Score 0 to 4;~* Ability to understand and consent to participate in this clinical trial, manifested by signing the Informed Consent Form (ICF).~Exclusion Criteria:~* Inability to ingest / absorb the study drug orally through spontaneous ingestion or use of gastro / enteral tubes;~* Any finding of clinical observation (history / physical evaluation) that is interpreted by the investigating physician as a risk to participate in the trial;~* Any laboratory test findings that the investigating physician considers as a risk to the research participant as to his / her participation in the clinical study;~* Any ECG examination finding that the investigating physician considers as a risk to the research participant as to his / her participation in the trial;~* Known hypersensitivity to the components of the drugs used during the study;~* Women in pregnancy or breastfeeding;~* Body weight less than 15kg;~* Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) \<30 mL / min;~* Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)\> 5 times the upper limit of normality;~* Refusal to participate;~* Refusal to sign the informed consent form.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): Standard of care (SOC) treatment
- SOC plus ivermectin 100 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 100 mcg/kg
- SOC plus ivermectin 200 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 200 mcg/kg
- SOC plus ivermectin 400 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 400 mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility